Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408946 | 0.72 | ABCG2 (0.46) | HPGDABCG2ABCB1NPC1RAB9A | |
| SCHEMBL4408406 | 0.69 | ABCG2 (0.44) | HPGDABCG2ABCB1NPC1RAB9A | |
| SCHEMBL10475779 | 0.69 | HPGD (0.57) | HPGDABCG2ABCB1NPC1RAB9A | |
| SCHEMBL4408852 | 0.69 | ABCG2 (0.46) | HPGDABCG2ABCB1NPC1RAB9A | |
| SCHEMBL4404185 | 0.69 | ABCG2 (0.46) | HPGDABCG2ABCB1NPC1RAB9A | |
| Hydrogen Peroxide SCHEMBL8609891 | 0.68 | PTPN1 (0.52) | PKM | |
| SCHEMBL1556937 | 0.68 | PTPN1 (0.52) | PKM | |
| SCHEMBL4406033 | 0.66 | ABCG2 (0.44) | HPGDABCG2ABCB1NPC1RAB9A | |
| SCHEMBL1585204 | 0.66 | TSHR (0.41) | PKM | |
| SCHEMBL4407303 | 0.65 | HPGD (0.57) | HPGDABCG2ABCB1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | HPGD 1718/4885ABCG2 1051/4885ABCB1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.